Phase 3 Trials Demonstrate Efficacy of Immune Checkpoint Inhibitors for Lung Cancer in Older Adults
Pharmacy Times,
Older patients’ underrepresentation in clinical trials leaves a gap in data regarding appropriate treatment.
Older patients’ underrepresentation in clinical trials leaves a gap in data regarding appropriate treatment.
Abstract Background The development of nonapoptotic programmed cell death inducers as anticancer agents has emerged as a cancer…
Byline: Jin Jiao, Wen-wen Li, Yan-hong Shang, Xiao-fang Li and Meng Jiao KEYWORDS: Advanced NSCLC, Chemotherapy, Immunotherapy…
It has been 20 years since the discovery of EGFR mutations and almost 25 years since we first used EGFR inhibitors in the clinic.